Bli medlem
Bli medlem

Du är här


Galapagos NV: Galapagos announces closing of NASDAQ IPO

Mechelen, Belgium; 19 May 2015 - Galapagos NV (Euronext&NASDAQ: GLPG)
announced today the closing of its global offering of 7,532,499 ordinary
shares, consisting of an underwritten public offering of 5,746,000 American
Depositary Shares ("ADSs"), at a price of $42.05 per ADS, before underwriting
discounts, and a concurrent European private placement of 1,786,499 ordinary
shares at a price of €37.00 per share, before underwriting discounts, for
gross proceeds of approximately €278.7 million ($316.7 million). This
includes the full exercise of the underwriters' greenshoe option to purchase
additional shares. All of the ordinary shares and the ADSs were offered by
Each of the ADSs offered represents the right to receive one ordinary share.
Galapagos' ordinary shares are listed on Euronext Amsterdam and Euronext
Brussels under the symbol "GLPG." The ADSs are listed on the NASDAQ Global
Select Market under the symbol "GLPG."
Morgan Stanley, Credit Suisse and Cowen and Company acted as joint
book-running managers, and Nomura and Bryan, Garnier&Co. acted as
co-managers, for the global offering.
A registration statement relating to these securities was declared effective
by the U.S. Securities and Exchange Commission on 13 May 2015.
Copies of the final prospectus for this offering may be obtained from Morgan
Stanley&Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, United
States, Attention: Prospectus Department; Credit Suisse Securities (USA) LLC,
One Madison Avenue, New York, NY, 10010, United States, Attention: Prospectus
Department, or by telephone at +1 (800) 221-1037, or by email at; or Cowen and Company, c/o Broadridge
Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, United
States, Attn.: Prospectus Department or by calling +1 (631) 274 2806.
This press release does not constitute an offer to sell nor a solicitation of
an offer to buy, nor shall there be any sale of securities, in any state or
jurisdiction in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or jurisdiction.
About Galapagos

Galapagos(Euronext&NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2 programs, two
Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule
and antibody programs in cystic fibrosis, inflammation, and other
indications. In the field of inflammation, AbbVie and Galapagos signed a
collaboration agreement for the development and commercialization
offilgotinib. Filgotinib is an orally-available, selective inhibitor of JAK1
for the treatment of rheumatoid arthritis and potentially other inflammatory
diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. Galapagos reported good activity and a favorable safety profile at
12 weeks in both the DARWIN 1 and 2 trials in RA. AbbVie and Galapagos also
signed a collaboration agreement in cystic fibrosis to develop and
commercialize molecules that address mutations in the CFTR gene.
PotentiatorGLPG1837is currently in a Phase 1 trial, and corrector GLPG2222 is
at the pre-clinical candidate stage. GLPG1205,a first-in-class inhibitor of
GPR84 and fully-owned by Galapagos, is currently being tested in a Phase 2
proof-of-concept trial in ulcerative colitis patients. GLPG1690, a fully
proprietary, first-in-class inhibitor of autotaxin, has shown favorable
safety in a Phase 1 trial and is expected to enter Phase 2 in idiopathic
pulmonary fibrosis. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Galapagos NV

Elizabeth Goodwin, Head of Corporate Communications&IR

Tel: +31 6 2291 6240
Galapagos forward-looking statements

This release may contain forward-looking statements, all of which involve
certain risks and uncertainties. These statements are often, but are not
always, made through the use of words or phrases such as "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates," "may,"
"will," "could," "stands to," "continues," "we believe," "we intend," as well
as similar expressions. Such forward-looking statements may involve known
and unknown risks, uncertainties and other factors which might cause the
actual results, financial condition, performance or achievements of
Galapagos, or industry results, to be materially different from any historic
or future results, financial conditions, performance or achievements
expressed or implied by such forward-looking statements. Among the factors
that may result in differences are the inherent uncertainties associated with
competitive developments, clinical trial and product development activities,
regulatory approval requirements and estimating the commercial potential of
our product candidates. A further list and description of these risks,
uncertainties and other risks can be found in the company's Securities and
Exchange Commission filing and reports, including in the company's prospectus
filed with the SEC on May 14, 2015 and future filings and reports by the
company. Given these uncertainties, the reader is advised not to place any
undue reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or

Important information

In the European Economic Area, this announcement is only addressed to and is
only directed at qualified investors within the meaning of Directive
2003/71/EC (as amended, and together with any applicable implementing
measures in any Member State, the "Prospectus Directive") ("Qualified
In addition, in the United Kingdom, this announcement is directed at and for
distribution only to Qualified Investors who are (i) persons who have
professional experience in matters relating to investments falling within
Article 19(5) of the Financial Services and Markets Act (Financial Promotion)
Order 2005, as amended (the "Order"), or (ii) persons who are high net worth
entities falling within Article 49(2)(a) to (d) of the Order, and (iii) other
persons to whom this announcement may otherwise lawfully be communicated (all
such persons together being referred to as "Relevant Persons"). The
securities referred to herein are only available to, and any invitation,
offer or agreement to subscribe, purchase or otherwise acquire such
securities will be engaged in only with Relevant Persons. Any person who is
not a Relevant Person should not act or rely on this communication or any of
its contents.
No announcement or information regarding the global offering may be
disseminated to the public in jurisdictions where a prior registration or
approval is required for such purpose. Other than the registration statement
filed with the U.S. Securities and Exchange Commission, no steps have been
taken, or will be taken, for the offering of ordinary shares or ADSs in any
jurisdiction where such steps would be required. The issue or sale of shares,
and the subscription for or purchase of shares, are subject to special legal
or statutory restrictions in certain jurisdictions. Galapagos NV is not
liable if these restrictions are not complied with by any person.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.